Targeted Protein Degradation Systems with Integrated AI, IoT, and Blockchain Technologies

This inventive concept integrates compounds for targeted protein degradation with AI, IoT, and blockchain technologies to create a more powerful and personalized system for treating diseases such as cancer.

The original patent disclosed compounds and methods for targeted degradation of enhancer of zeste homolog 2 polypeptide. However, these compounds have limited efficacy and specificity. The new inventive concept addresses these limitations by combining the compounds with AI-driven analysis, IoT-enabled sensors, and blockchain-secured payloads to create a more effective and personalized system.

The inventive concept consists of a compound having the chemical structure ULM-L-PTM, which binds to an E3 ubiquitin ligase and a target protein, respectively. The compound is integrated with a machine learning module that predicts optimal ubiquitin ligase-target protein combinations. The system also includes a blockchain-secured payload and IoT-enabled sensors for monitoring the subject's response. Additionally, the system may utilize AI-driven simulations to design novel materials with enhanced bioavailability.

The new inventive concept combines the compounds of the original patent with AI, IoT, and blockchain technologies, which is not obvious from the original patent. The integration of these technologies provides a synergistic effect, resulting in a more effective and personalized system.

Alternative embodiments may include using different AI algorithms, IoT-enabled devices, or blockchain platforms. The system may also be adapted for use in various diseases or conditions, such as neurodegenerative disorders or infectious diseases.

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the development of personalized medicines for cancer and other diseases. The integration of AI, IoT, and blockchain technologies also opens up opportunities for partnerships and collaborations with companies in these fields.